MultiSCRIPT has recently achieved a major milestone with 1st patient enrolled on February 5th, 2024 in Basel. Since then, over 150 participants have been enrolled and randomized in less than 3 months (anticipated recruitment is 915 participants over a 2-year period).
This is a testament that keeping things simple and fully embedded in the patient’s care contributes to a smooth recruitment. MultiSCRIPT is a pragmatic clinical trial that's embedded within the Swiss MS cohort, and it seeks to assess the benefits of 6-monthly sNfL (serum neurofilament light chain) monitoring in addition to usual care compared to usual care alone. The trial aims to provide further evidence and insights into the potential advantages of incorporating sNfL monitoring into routine clinical practices to inform more personalized strategies for multiple sclerosis (MS).
For those who are interested in learning more about MultiSCRIPT-Cycle 1, a detailed protocol is available as a preprinthttps://www.medrxiv.org/content/10.1101/2024.03.22.24304720v1
We encourage you to check it out and share it with others who might find it useful.
We would like to express our gratitude to the study coordinators, nurses, and physicians at the MS center in Basel, whose hard work and dedication have made this achievement possible. Thank you to the Swiss National Science Foundation for supporting this Investigator Initiated Trial.
We are also pleased to announce that we will initiate the other SMSC centers soon, including Ospedale Regionale di Lugano, University Hospital Geneva, University Hospital Lausanne, Inselspital Bern, Kantonsspital Aarau, University Hospital Zürich, and Kantonsspital St. Gallen.
If you're interested in learning more about our awesome team and contributors, we encourage you to visit the multiSCRIPT website at the following URL: https://multiscript.rc2nb.ch
We are excited about the progress and believe that MultiSCRIPT will significantly improve the lives of people with MS.
